# C4221008; PHAROS (NCT03915951)

> An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03915951
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Pfizer
- Conditions: Non-small Cell Lung Cancer
- Interventions: encorafenib; binimetinib
- Enrollment: 98
- Primary outcome: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 25
- YouTube: 3
- Podcasts: 3
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=c4221008-pharos-nct03915951

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03915951", "email": "<work email>"}; the inbox owner confirms by the emailed link.